

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

UBRAJABEAI, UBRAJABET: Abemaciclib for Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer

Highlights of Revised Protocols

DPYD Tests Clarified in Fluorouracil and Capecitabine Protocols

Continuing Education

Family Practice Oncology Network

Continuing Medical Education: Colorectal Cancer Current Screening Recommendations and Follow-Up Care

Cancer Drug Manual®

New: Lorlatinib **Revised:** Abemaciclib, asciminib, carmustine; Chemotherapy and Stability Chart: carmustine

Benefit Drug List

New: UBRAJABEAI, UBRAJABET

NEW Protocols, PPOs and Patient Handouts

BR UBRAJABEAI, UBRAJABET

REVISED Protocols, PPOs and Patient Handouts

BR BRAJLHRHAI, UBRAJOLA, BRAVEVEX, BRAVLHRHAI, BRAVPALAI, BRAVPBFLV, BRAVRBFLV, BRAVRIBAI | **GI** UGIAVPANEN, GIAVPG, GILEN | **GO** GOENDAVCAT, GOENDAVPL, GOENDAVPL6 | **GU** GUAVPEML, GUAVPEML6, GUNAJPG | **HN** HNAVPMBM, HNAVPMBM6, HNOTLEN | **LK** ULKCMLP | **LY** LYASPMEDEX, LYCHOPRMTX, LYCODOXMR, LYHDMRTEM, LYHDMTXPRO, LYSMILE, ULYVENETO, ULYVENETOR | **Fluorouracil and Capecitabine Protocols** BRAJCAP, BRAJFEC, BRAJFECF, BRAJFECDF, BRAVCAP, BRAVCMF, BRAVLCAP, BRAVTCAP, UBRAVTTCAP, GIAJCAP, GIAJCAPOX, GIAJFFOX, GIAJFL, GIAVCAP, GIAVCAPB, GIAVCRT, GIAVFL, GIAVTZCAP, GIBAJCAP, GICAPIRI, GICAPOX, GICART, GICIRB, GICOXB, GICPART, GIEFFOXRT, GIENDO2, GIFFIRB, GIFFIRPAN, GIFFOXB, GIFFOXPAN, GIFIRINOX, GIFOLFIRI, GIFOLFOX, GIFUART, GIFUC, GIFUPART, GIGAJCOX, GIGAJCPRT, GIGAJFFOX, GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVCOX, GIGAVCOXN, GIGAVCOXP, GIGAVCOXT, GIGAVFFOX, GIGAVFFOXN, GIGAVFFOXP, GIGAVFFOXT, GIGECC, GIGFLODOC, GIGFOLFIRI, GIPAJFIROX, GIPAJGCAP, GIPAVCAP, GIPAVFFIRI, GIPAVFFOX, GIRAJCOX, GIRAJFFOX, GIRCAP, GIRCRT, GIRINFRT, GUFUPRT, HNAVCAP, HNAVFUFA, HNAVFUP, HNAVPFPMB, HNLACAFRT, HNLADCF, HNNAVCAP, HNNAVFUFA, HNNAVFUP, HNSAVFAC, HNSAVFUP

Resources and Contact Information

Editor's Choice

New Programs

Effective 01 December 2023, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Breast

Abemaciclib for Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer (UBRAJABEAI, UBRAJABET) – The BC Cancer Breast Tumour Group is introducing adjuvant abemaciclib in combination with endocrine therapy for patients with hormone receptor positive, HER2-negative, node-positive, fully resected early breast cancer at high risk of disease recurrence (Ki-67 score \geq 20%). Abemaciclib may be combined with aromatase inhibitor with or without LHRH agonist (UBRAJABEAI), or with tamoxifen with or without LHRH agonist (UBRAJABET).

In the phase III monarchE trial, the addition of abemaciclib to endocrine therapy was shown to improve invasive disease-free survival (hazard ratio 0.64). The addition of abemaciclib was associated with slightly more adverse events, including diarrhea, neutropenia, and fatigue, although the safety profile was consistent with the known adverse effect profile of CDK 4/6 inhibitors and most are considered manageable with dose modifications and supportive care.[1]

1. CADTH Reimbursement Recommendation Abemaciclib (Verzenio): in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score of at least 20%. Oct 2022.

Highlights of Revised Protocols

DPYD Tests Clarified in Fluorouracil and Capecitabine Protocols

Protocols containing fluorouracil and/or capecitabine have been clarified to emphasize that *DPYD* genotyping test is NOT required if:

1. Patient has previously tolerated fluorouracil or capecitabine, or
2. Patient has previously tested for *DPYD* genotyping.

Continuing Education

Family Practice Oncology Network Continuing Medical Education

The Family Practice Oncology Network (FPON) is pleased to announce a complimentary accredited webinar session on 'Colorectal Cancer Current Screening Recommendations and Follow-Up Care' on **Thursday, 18 January, from 8 am to 9 am**, as part of the ongoing Complimentary Accredited Webinar Series. This session will cover:

- Risk factors for the development of colon cancer and their impact on screening strategy;
- Current colon screening and surveillance recommendations;
- Follow-up recommendations post-colorectal cancer treatment.

This session is offered at **no charge** and is accredited at up to 1.0 Mainpro+ credits.

For more information and links to registration, visit the FPON Continuing Medical Education site at fpon.ca or <https://ubccpd.ca/learn/learning-activities/course?eventtemplate=661-fpon-webinar-colorectal-cancer-current-screening-recommendations-and-followup-care>

Cancer Drug Manual[©]

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Lorlatinib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Lorlatinib is an orally administered 3rd generation tyrosine kinase inhibitor which targets anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1). Lorlatinib is used in the treatment of non-small cell lung cancer. Usual dosing is 100 mg PO once daily.

Highlights from these documents include:

- lorlatinib starting dose adjustment may be required to manage some drug interactions
- concurrent administration of strong CYP 3A inducers with lorlatinib may cause serious hepatotoxicity; the CYP 3A inducer should be discontinued prior to initiating lorlatinib
- hyperlipidemia is frequently reported; lipid-lowering therapy may be required
- CNS adverse effects are common and can include cognitive impairment, mood disorders, speech disturbances, or sleep disorders

Lorlatinib has been added to the **Auxiliary Label List** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Abemaciclib Monograph and Patient Handout

Dosage Guidelines: bolded and italicized BC Cancer standard dosing and updated references to include new BC Cancer protocols UBRAJABEAI and UBRAJABET

Patient Handout: updated template wording throughout; updated *nausea/vomiting* and *diarrhea* in *Side Effects* table to include new messaging about dehydration

Asciminib Monograph

Cautions: updated *Hepatitis B reactivation* bullet to include link to new BC Cancer protocol SCHBV for recommended HBV screening and prophylaxis

Carmustine Monograph and Chemotherapy Preparation and Stability Chart

Supply and Storage: updated to reflect current contract brands (added SteriMax brand; deleted Marcan brand); updated references where applicable for brand-specific information to reflect brand change

Solution Preparation and Compatibility and Parenteral Administration table: updated references where applicable

Chemotherapy Preparation and Stability Chart: added SteriMax brand; deleted Marcan brand

Benefit Drug List

New Programs

Effective 01 December 2023, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	Restricted
Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	Restricted

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol Title	Protocol	PPPO	Handout
UBRAJABEI	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
UBRAJABET	Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJLHRHAI	Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	<i>Title and eligibility updated</i>	--	--
UBRAJOLA	Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib	<i>Eligibility updated and exclusions clarified</i>	--	--
BRAVEVEX	Therapy for Advanced Breast Cancer Using Everolimus and Exemestane	<i>Eligibility updated</i>	--	--
BRAVLHRHAI	Therapy for Advanced Breast Cancer using a LHRH Agonist and an Aromatase Inhibitor	<i>Eligibility updated</i>	--	--
BRAVPALAI	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Eligibility updated, buserelin every 6 weeks option deleted</i>	<i>Buserelin every 6 weeks option deleted</i>	--
BRAVPBFLV	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant With or Without LHRH Agonist	<i>Eligibility updated, buserelin every 6 weeks option deleted</i>	<i>Buserelin every 6 weeks option deleted</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BRAVRBFLV	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant With or Without LHRH Agonist	<i>Eligibility updated, buserelin every 6 weeks option deleted</i>	<i>Buserelin every 6 weeks option deleted</i>	--
BRAVRIBAI	Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Eligibility updated, buserelin every 6 weeks option deleted</i>	<i>Buserelin every 6 weeks option deleted</i>	--
GI Gastrointestinal				
UGIAVPANEN	Treatment of BRAF V600E - Mutated Metastatic Colorectal Cancer using PANitumumab and Encorafenib	<i>Creatinine added to Tests prior to each cycle</i>	<i>Creatinine added to Tests prior to each cycle</i>	--
GIAVPG	First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and CISplatin	<i>Tests clarified, highly emetogenic antiemetics added for Carboplatin</i>	<i>Highly emetogenic antiemetics added for Carboplatin</i>	--
GILEN	First Line Therapy of Advanced Hepatocellular Carcinoma Using Lenvatinib	--	<i>Diarrhea deleted from pre-treatment metric</i>	--
GO Gynecological				
GOENDAVCAT	Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel	<i>Eligibility updated</i>	--	--
GOENDAVPL	Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	<i>Title, eligibility, exclusions updated, INR deleted from baseline Tests</i>	--	--
GOENDAVPL6	Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using 6-weekly Pembrolizumab and Lenvatinib	<i>Title, eligibility, exclusions updated, INR deleted from baseline Tests</i>	--	--
GU Genitourinary				
GUAVPEML	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib	<i>INR deleted from baseline Tests</i>	--	--
GUAVPEML6	Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib	<i>INR deleted from baseline Tests</i>	--	--
GUNAJPG	Neo-Adjuvant Therapy for Urothelial Carcinoma using CISplatin and Gemcitabine	<i>Contact physicians, eligibility, exclusions, tests and references updated, carboplatin option deleted</i>	<i>Carboplatin option deleted</i>	
HN Head and Neck				

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
HNAVPMBM	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	<i>Baseline morning serum cortisol deleted</i>	--	--
HNAVPMBM6	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab	<i>Baseline morning serum cortisol deleted</i>	--	--
HNOTLEN	Therapy for Locally Recurrent or Metastatic, RAI-refractory Differentiated Thyroid Cancer Using Lenvatinib	--	<i>Diarrhea deleted from pre-treatment metric</i>	--
LK Leukemia				
ULKCMPLP	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONatinib	<i>Agency name updated, electrolytes clarified in Tests, echocardiogram added at 3 months</i>	<i>Electrolytes clarified in Tests, echocardiogram added at 3 months</i>	--
LY Lymphoma				
LYASPMEDX	Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma Using Pegaspargase, Methotrexate and Dexamethasone	<i>Prochlorperazine dosing scheduled updated</i>	--	--
LYCHOPRMTX	Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and ritUXimab in Diffuse Large B-Cell Lymphoma	<i>Prochlorperazine dosing scheduled updated</i>	--	--
LYCODOXMR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRISTine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and ritUXimab	<i>Prochlorperazine dosing scheduled updated</i>	--	--
LYHDMRTEM	Treatment of Primary and Secondary CNS Lymphoma with High Dose Methotrexate, ritUXimab and temozolomide	<i>Prochlorperazine dosing scheduled updated</i>	--	--
LYHDMTXPRO	Central Nervous System Prophylaxis with High Dose Methotrexate in Diffuse Large B-Cell Lymphoma	<i>Prochlorperazine dosing scheduled updated</i>	--	--
LYSMILE	Treatment of Natural Killer or T-Cell Lymphoma Using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide	<i>Prochlorperazine dosing scheduled updated</i>	--	--
ULYVENETO	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax	--	<i>Same day lab order deleted (Ramp-up phase: Low or Medium TLS Risk)</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LYVENETOR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and ritUXimab	--	<i>Same day lab order deleted (Ramp-up phase: Low or Medium TLS Risk)</i>	--

Fluorouracil and capecitabine protocols have been revised to include baseline *DPYD* testing and hyperlink to dosing recommendations based on *DPYD* Activity Score:

Code	Protocol Title
BRAJCAP	Therapy of Adjuvant Breast Cancer using Capecitabine
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFECDD	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and DOCetaxel
BRAJFECDDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by DOCetaxel and Trastuzumab
BRAVCAP	Therapy for Metastatic Breast Cancer Using Capecitabine
BRAVCMF	Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil
BRAVLCAP	Therapy for Metastatic Breast Cancer Using Capecitabine and Lapatinib
BRAVTCAP	Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab and Capecitabine
UBRAVTTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib, and Capecitabine
GIAJCAP	Adjuvant Therapy of Colon Cancer Using Capecitabine
GIAJCAPOX	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIAJFL	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVCAP	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
GIAVCAPB	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine and Bevacizumab
GIAVCRT	Combined Modality Therapy for Metastatic Rectal Carcinoma using Capecitabine and Radiation Therapy
GIAVFL	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion
GIAVTZCAP	Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine
GIBAJCAP	Adjuvant Therapy of Biliary Cancer using Capecitabine
GICAPIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuited for GOLFIRI
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
GICART	Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
GICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine

Code	Protocol Title
GICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
GICPART	Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy
GIEFFOXRT	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy
GIENDO2	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and DOXOrubicin
GIFFIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin and Bevacizumab
GIFFIRPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin, and PANitumumab
GIFFOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
GIFFOXPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin, and PANitumumab
GIFIRINOX	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
GIFOLFIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
GIFOLFOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIFUART	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using Mitomycin, Fluorouracil and Radiation Therapy
GIFUC	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer Using Infusional Fluorouracil and CISplatin
GIFUPART	Combined Modality Curative Therapy for Carcinoma of the Anal Canal Using CISplatin, Infusional Fluorouracil and Radiation Therapy
GIGAJCOX	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin and Capecitabine
GIGAJCPRT	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy
GIGAJFFOX	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin, Fluorouracil, and Leucovorin
GIGAVCC	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using CISplatin and Capecitabine
GIGAVCCT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using CISplatin, Capecitabine and Trastuzumab
GIGAVCFT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab
GIGAVCOX	Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin
GIGAVCOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Capecitabine, Oxaliplatin, and Trastuzumab

Code	Protocol Title
GIGAVFFOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin
GIGAVFFOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced HER-2 Positive Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab
GIGECC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Capecitabine
GIGFLODOC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using DOCETaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin
GIGFOLFIRI	Second Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma Using Irinotecan, Fluorouracil and Leucovorin
GIPAJFIROX	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
GIPAJGCAP	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine
GIPAVCAP	Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
GIPAVFFIRI	Second Line Treatment for Metastatic Pancreatic Cancer Using Irinotecan, Fluorouracil and Leucovorin
GIPAVFFOX	Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer Using Oxaliplatin, Fluorouracil, and Leucovorin
GIRAJCOX	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine
GIRAJFFOX	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine
GIRCRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy
GIRINFRT	Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy
GUFUPRT	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and CISplatin with Radiation
HNAVCAP	Treatment Of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck With Capecitabine
HNAVFUFA	Fluorouracil and Leucovorin for Recurrent Head and Neck Cancer (Squamous Cell Carcinoma)
HNAVFUP	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
HNAVFPMB	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Using Platinum, Fluorouracil and Pembrolizumab
HNLACAFRT	Combined Chemotherapy (CARBOplatin and Fluorouracil) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
HNLADCF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with DOCETaxel, CISplatin and Infusional Fluorouracil
HNNAVCAP	Treatment Of Recurrent Or Metastatic Nasopharyngeal Cancer With Capecitabine
HNNAVFUFA	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Fluorouracil and Leucovorin

Code	Protocol Title
HNNAVFUP	Treatment for Advanced Nasopharyngeal Cancer of the Head and Neck using Platinum and Fluorouracil
HNSAVFAC	Palliative Therapy for Advanced Salivary Gland Cancers Using Cyclophosphamide, DOXOrubicin and Fluorouracil
HNSAVFUP	Treatment of Advanced Head and Neck Cancer Using CISplatin and Fluorouracil

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
Jeevan Dosanjh, RN, BScN
Alina Gerrie, MD, MPH, FRCPC

Samuel Hackett, RN, BScN, CON(C)
Alison Pow, BScPharm